Back to Search
JESSICA BERENSON, MD
MD
Pediatric Critical Care Medicine Physician
NPI: 1568726891Individual
Specialties, Licenses & Credentials
Pediatrics Physician
Pediatrics
Code: 208000000X
0116024655(VA)
Pediatric Critical Care Medicine PhysicianPrimary
Pediatrics — Pediatric Critical Care Medicine
Code: 2080P0203X
036.140566(IL)
Research & Publications (20)
Regulation of prostate-specific antigen expression by the junctional adhesion molecule A.
PMID 18602143·Urology·2009
4-observational
Hematology: Bortezomib in newly diagnosed multiple myeloma.
PMID 19390550·Nat Rev Clin Oncol·2009
8-other
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
PMID 19226361·Eur J Haematol·2009
3-trial
Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis.
PMID 19060246·Blood·2009
7-preclinical
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
PMID 19188182·Clin Cancer Res·2009
3-trial
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
PMID 19471019·Blood·2009
3-trial
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
PMID 18424742·J Immunol·2008
8-other
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.
PMID 18927277·Clin Cancer Res·2008
6-review
The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement.
PMID 18509352·Leukemia·2008
8-other
Comparison of twin and autologous transplants for multiple myeloma.
PMID 18804041·Biol Blood Marrow Transplant·2008
3-trial
NF-kappaB in the pathogenesis and treatment of multiple myeloma.
PMID 18536579·Curr Opin Hematol·2008
6-review
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
PMID 18463870·Ann Hematol·2008
3-trial
Pleiotrophin, a multifunctional angiogenic factor: mechanisms and pathways in normal and pathological angiogenesis.
PMID 18391787·Curr Opin Hematol·2008
6-review
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
PMID 18783399·Br J Haematol·2008
3-trial
Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.
PMID 18829511·Clin Cancer Res·2008
3-trial
Proteasome inhibitors: closing the garbage can opens up new therapeutic options for patients with B-cell malignancies.
PMID 17877842·Clin Lymphoma Myeloma·2007
6-review
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
PMID 17587338·Br J Haematol·2007
7-preclinical
Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment.
PMID 17578909·Proc Natl Acad Sci U S A·2007
7-preclinical
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma.
PMID 17562244·Clin Lymphoma Myeloma·2007
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5721 S MARYLAND AVE # 8016K155, COMER CHILDREN'S HOSPITAL
CHICAGO, IL 60637 - Phone
- (773) 702-7553
Quick Facts
- NPI
- 1568726891
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile